Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 54 | 124 | 168 | 1,061 | 1,274 |
| Receivables | N/A | N/A | 64 | N/A | 74 |
| TOTAL | $102 | $186 | $274 | $1,200 | $1,378 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 13,188 | 13,226 | 61,328 | 195,312 | 205,833 |
| TOTAL | $13,188 | $13,226 | $61,328 | $195,312 | $205,833 |
| Total Assets | $13,289 | $13,412 | $61,602 | $196,512 | $207,211 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 326 | 164 | 3,494 | 2,771 | 1,125 |
| TOTAL | $452 | $794 | $3,494 | $2,771 | $1,125 |
| Non-Current Liabilities | |||||
| Long Term Debt | 566 | 566 | 1,566 | 566 | N/A |
| Other Non-Current Liabilities | 7,291 | 7,054 | 51,541 | 188,175 | 201,077 |
| TOTAL | $7,837 | $7,618 | $53,108 | $188,741 | $201,086 |
| Total Liabilities | $8,289 | $8,412 | $56,602 | $191,512 | $202,211 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 2 | 2 | 2 | 7 | 7 |
| Common Shares | 1 | 1 | 1 | 1 | 1 |
| Retained earnings | 4,936 | 4,717 | 2,107 | -137 | 3,775 |
| TOTAL | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 |
| Total Liabilities And Equity | $13,289 | $13,412 | $61,602 | $196,512 | $207,211 |